(Hypertension. 1997;30:886-896.)
© 1997 American Heart Association, Inc.
Articles |
Ouabain-like Factor Quantification in Mammalian Tissues and Plasma
Comparison of Two Independent Assays
From Prassis-Sigma Tau, Research Institute, Milan (M.F., P.F.), the Division of Nephrology and Hypertension, University of Milan and S. Raffaele Hospital (P.M., G.B.), Milan, and the CNR Institute of Clinical Physiology, Pisa (S.B.), Italy; and the Department of Physiology, School of Medicine, University of Maryland, Baltimore (J.M.H.).
Correspondence to Dr P. Ferrari, Prassis Istituto Ricerche Sigma-Tau, Via Forlanini 3, 20019 Settimo Milanese, Milano, Italy. E-mail mc3405{at}mclink.it
Abstract The resolution of controversies that concern the detectability of an endogenous ouabain-like factor (OLF) in mammalian tissues and plasma was approached by the application of a standardized method for its extraction and quantification. Two independent assays were used to quantify the OLF: (1) a radioimmunoassay, which used a polyclonal antiouabain antiserum, and (2) a radioenzymatic assay based on the inhibition of dog kidney Na+,K+-ATPase. Plasma and tissues were obtained from the Milan hypertensive strain (MHS) and the Milan normotensive strain (MNS) of rats and from healthy human volunteers. Results indicate that (1) a single high-performance liquid chromatography (HPLC) fraction identical to that of ouabain was identified by both assay methods in the rat hypothalamus and hypophysis and in both rat and human plasma; (2) dilution curves of OLF and standard ouabain were parallel and with a similar Kd, both in radioimmunoassay (3 nmol/L) and ATPase assay (14 nmol/L); (3) after HPLC, OLF was similarly quantified by the two methods in the hypothalamus, hypophysis, adrenals, and plasma of rats and in human plasma; (4) OLF was present in larger amounts in the hypothalamus, hypophysis, and plasma of MHS rats than that of MNS rats; (5) the HPLC fraction of human plasma was quantified similarly by both assays (range, 60 to 150 pmol/L); (6) recovery of standard ouabain in pre-HPLC plasma extracts was approximately 90%; and (7) pre-HPLC OLF concentrations in human plasma ranged between 0.05 and 0.75 nmol/L. Rat cerebral tissues and both rat and human plasma contained measurable amounts of OLF, which were quantified similarly by radioimmunoassay and ATPase assay, both before and after HPLC fractionation. The increased MHS tissue and plasma levels of OLF are in keeping with the pathogenetic role of this factor in MHS hypertension.
Key Words: ouabain • Na+,K+-ATPase • rats • human • tissue • plasma
This article has been cited by other articles:
 |
|
 |
|
  D. E. Anderson, O. V. Fedorova, C. H. Morrell, D. L. Longo, V. A. Kashkin, J. D. Metzler, A. Y. Bagrov, and E. G. Lakatta Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1248 - R1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Orlov and A. A. Mongin Salt-sensing mechanisms in blood pressure regulation and hypertension Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2039 - H2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Pitzalis, J. M. Hamlyn, E. Messaggio, M. Iacoviello, C. Forleo, R. Romito, E. de Tommasi, P. Rizzon, G. Bianchi, and P. Manunta Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy Eur J Heart Fail, March 1, 2006; 8(2): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Blaustein, J. Zhang, L. Chen, and B. P. Hamilton How does salt retention raise blood pressure? Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R514 - R523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ferrari, M. Ferrandi, G. Valentini, and G. Bianchi Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R529 - R535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manunta, B. P. Hamilton, and J. M. Hamlyn Salt intake and depletion increase circulating levels of endogenous ouabain in normal men Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R553 - R559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Murrell, J. D. Randall, J. Rosoff, J.-l. Zhao, R. V. Jensen, S. R. Gullans, and G. T. Haupert Jr Endogenous Ouabain: Upregulation of Steroidogenic Genes in Hypertensive Hypothalamus but Not Adrenal Circulation, August 30, 2005; 112(9): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferrandi, I. Molinari, P. Barassi, E. Minotti, G. Bianchi, and P. Ferrari Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238 J. Biol. Chem., August 6, 2004; 279(32): 33306 - 33314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Echevarria-Lima, E. G. de Araujo, L. de Meis, and V. M. Rumjanek Ca2+ Mobilization Induced by Ouabain in Thymocytes Involves Intracellular and Extracellular Ca2+ Pools Hypertension, June 1, 2003; 41(6): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H.G Schwinger, H. Bundgaard, J. Muller-Ehmsen, and K. Kjeldsen The Na, K-ATPase in the failing human heart Cardiovasc Res, March 15, 2003; 57(4): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Parhami-Seren, R. Haberly, M. N. Margolies, and G. T. Haupert Jr Ouabain-Binding Protein(s) From Human Plasma Hypertension, August 1, 2002; 40(2): 220 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Matthay, H. G. Folkesson, and C. Clerici Lung Epithelial Fluid Transport and the Resolution of Pulmonary Edema Physiol Rev, July 1, 2002; 82(3): 569 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Aizman, P. Uhlen, M. Lal, H. Brismar, and A. Aperia Ouabain, a steroid hormone that signals with slow calcium oscillations PNAS, October 25, 2001; (2001) 221315298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. De Wardener The Hypothalamus and Hypertension Physiol Rev, October 1, 2001; 81(4): 1599 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Aileru, A. De Albuquerque, J. M. Hamlyn, P. Manunta, J. R. Shah, M. J. Hamilton, and D. Weinreich Synaptic plasticity in sympathetic ganglia from acquired and inherited forms of ouabain-dependent hypertension Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2001; 281(2): R635 - R644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manunta, E. Messaggio, C. Ballabeni, M. T. Sciarrone, C. Lanzani, M. Ferrandi, J. M. Hamlyn, D. Cusi, F. Galletti, and G. Bianchi Plasma Ouabain-Like Factor During Acute and Chronic Changes in Sodium Balance in Essential Hypertension Hypertension, August 1, 2001; 38(2): 198 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Balzan, D. Neglia, S. Ghione, G. D'Urso, M. C. Baldacchino, U. Montali, and A. L'Abbate Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction Eur J Heart Fail, March 1, 2001; 3(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Vakkuri, S. S. Arnason, P. Joensuu, J. Jalonen, O. Vuolteenaho, and J. Leppaluoto Radioiodinated Tyrosyl-Ouabain and Measurement of a Circulating Ouabain-like Compound Clin. Chem., January 1, 2001; 47(1): 95 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. A. M. Qazzaz, M. A. El-Masri, and R. Valdes Jr. Secretion of a Lactone-Hydrogenated Ouabain-Like Effector of Sodium, Potassium-Adenosine Triphosphatase Activity by Adrenal Cells Endocrinology, September 1, 2000; 141(9): 3200 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Parhami-Seren, C. Bell, M. N. Margolies, and G. T. Haupert Jr. Monoclonal Antibodies That Distinguish Between Two Related Digitalis Glycosides, Ouabain and Digoxin J. Immunol., October 15, 1999; 163(8): 4360 - 4366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manunta, P. Stella, R. Rivera, D. Ciurlino, D. Cusi, M. Ferrandi, J. M. Hamlyn, and G. Bianchi Left Ventricular Mass, Stroke Volume, and Ouabain-Like Factor in Essential Hypertension Hypertension, September 1, 1999; 34(3): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kawamura, J. Guo, Y. Itagaki, C. Bell, Y. Wang, G. T. Haupert Jr., S. Magil, R. T. Gallagher, N. Berova, and K. Nakanishi On the structure of endogenous ouabain PNAS, June 8, 1999; 96(12): 6654 - 6659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferrari, L. Torielli, M. Ferrandi, G. Padoani, L. Duzzi, M. Florio, F. Conti, P. Melloni, L. Vesci, N. Corsico, et al. PST2238: A New Antihypertensive Compound That Antagonizes the Long-Term Pressor Effect of Ouabain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 83 - 94. [Abstract] [Full Text]
|
|
|
|
|
|
O. Aizman, P. Uhlen, M. Lal, H. Brismar, and A. Aperia Ouabain, a steroid hormone that signals with slow calcium oscillations PNAS, November 6, 2001; 98(23): 13420 - 13424. [Abstract] [Full Text] [PDF]
|
|